Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-10-22

FDA Approved: SUSVIMO — Original Application (Genentech, Inc.)

View source ↗

Summary

FDA approved SUSVIMO, a port delivery system delivering ranibizumab, for the treatment of wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUSVIMO (Ranibizumab)

Snippet

ORIG AP for SUSVIMO (RANIBIZUMAB)